key: cord-0822231-prikm9cp
authors: Chang Villacreses, Maria Mercedes; Karnchanasorn, Rudruidee; Panjawatanan, Panadeekarn; Ou, Horng-Yih; Chiu, Ken C
title: Conundrum of vitamin D on glucose and fuel homeostasis
date: 2021-09-15
journal: World J Diabetes
DOI: 10.4239/wjd.v12.i9.1363
sha: 2d7e5583214e281824bfedfdd1b9a02e3784350f
doc_id: 822231
cord_uid: prikm9cp

As an endocrine hormone, vitamin D plays an important role in bone health and calcium homeostasis. Over the past two decades, the non-calcemic effects of vitamin D were extensively examined. Although the effect of vitamin D on beta cell function were known for some time, the effect of vitamin D on glucose and fuel homeostasis has attracted new interest among researchers. Yet, to date, studies remain inconclusive and controversial, in part, due to a lack of understanding of the threshold effects of vitamin D. In this review, a critical examination of interventional trials of vitamin D in prevention of diabetes is provided. Like use of vitamin D for bone loss, the benefits of vitamin D supplementation in diabetes prevention were observed in vitamin D-deficient subjects with serum 25-hydroxyvitamin D < 50 nmol/L (20 ng/mL). The beneficial effect from vitamin D supplementation was not apparent in subjects with serum 25-hydroxyvitamin D > 75 nmol/L (30 ng/mL). Furthermore, no benefit was noted in subjects that achieved serum 25-hydroxyvitamin D > 100 nmol/L (40 ng/mL). Further studies are required to confirm these observations.

The potential role of vitamin D deficiency induced by migration of human beings has been suggested to be involved in human evolution and various modern health conditions [1] . The history prospective of vitamin D evaluation will enhance our understanding of the development in this field. The role of dietary deficiency in the pathogenesis of rickets was established by Platt[2] in 1919. Although it was thought to be caused by vitamin A deficiency initially, McCollum et al [3] identified a vitamin deficiency other than vitamin A that caused rickets in 1922. Since vitamin A, B, and C were already identified, the new molecule was named as vitamin D [4] .

Beginning with its discovery in 1922, scientific publications focusing upon vitamin D numbered no more than some 10 per year but this increased to 35 per year by 1945 ( Figure 1 ). As knowledge of the structure, molecular biology and function of vitamin D increased 

The role of vitamin D on calcium and bone metabolism was well-summarized [9] . There is no doubt about the association between rickets and vitamin D deficiency and the reversal and prevention of rickets with vitamin D supplementation. However, controversy still surrounds the efficacy of vitamin D supplementation upon bone mineral density and fracture prevention. Multiple studies failed to demonstrate any benefit from vitamin D supplementation[10-12] and a systematic review and metaanalysis also failed to confirm any beneficial effect on bone density or fracture prevention from vitamin D supplement [13] . Nevertheless, placebo-control randomized clinical trials revealed a threshold effect of vitamin D [14, 15] with no benefit observed on the subjects with baseline 25-hydroxyvitamin D level ≥ 75 nmol/L (30 ng/mL). Furthermore, possible detrimental effects on bone mineral density were observed in subjects who received a higher dose of vitamin D (250 μg or 10000 IU daily) with a mean 25-hydroxyvitamin D of 200 nmol/L or 80 ng/mL [12] . While not conclusive, these data suggest that the optimal effects of vitamin D are found at a 25hydroxyvitamin D level of 75 nmol/L (30 ng/mL).

Vitamins are defined as micronutrients that cannot be self-synthesized and that necessary for the proper function of key enzymatic processes. Consequently, vitamins must be obtained through the diet. Vitamin D is synthesized from cholesterol to 7dehydrocholesterol, also known as pro-vitamin D 3 , in the skin through the action of ultraviolet radiation [16] . In addition, the liver forms 25-hydroxyvitamin D 3 , also known as pre-vitamin D 3 . To become an active compound, further hydroxylation in the kidney is required to form 1,25-dihydroxyvitaomin D 3 , which is a biologically active vitamin D. Then, 1,25-dihydroxyvitamin D is released into circulation to exert its effects on the target cells and promote calcium and bone homeostasis. Thus, vitamin D is a hormone and, like the pituitary-thyroid axis, has a complex natural history in the body (Table 1) .

The half-life of thyroid hormone depends upon thyroid status [17] . The half-life for levothyroxine (T4) is 6-7 d in euthyroid subjects, 9-10 d in subjects with hypothyroidism, and 3-4 d in subjects with hyperthyroidism. The half-life of liothyronine (T3) is 18-24 h in euthyroid subjects, 12-16 h in hyperthyroid subjects, and 26-32 h in hypothyroid subjects. The half-life of vitamin D averages 15 h but depends upon of the type of vitamin D (cholecalciferol or vitamin D 3 vs ergocalciferol or vitamin D 2 ) and vitamin D binding protein concentration [18] . The half-life of 1,25-dihydroxyvitamin D is 10-20 h [19] , while there is no information regarding the half-life of 1,25dihydroxyvitamin D 3 vs D 2 . Since 1,25-dihydroxyvitamin D is released into the blood and exerts its effects upon osteocytes to promote mineralization and on the gastrointestinal epithelium to increase calcium and phosphorus absorption, it is appropriate to classify vitamin D as a hormone. In contrast to calcemic effects of vitamin D which is primary mediated by circulating 1,25-dihydroxyvitamin D produced in the kidney, the non-calcemic effects of vitamin D are mediated by circulating 25-hydroxyvitamin D through a paracrine or autocrine function [29] . Within the target cells or its vicinity, circulatory 25-hydroxyvitamin D 

In patients with vitamin D deficiency and diabetes, vitamin D supplementation improved beta cell function and glucose tolerance [70] . An association between vitamin D deficiency and glucose intolerance and beta cell dysfunction was observed in east London Asians [71] . Similarly, alternations in vitamin D metabolism in obese subjects manifesting as low 25-hydroxyvitaimin D is well-recognized [72] . This topic will be reviewed in this article. 

Vitamin D is available in two forms: ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ). Ergocalciferol comes from plants in the form of ergosterol (provitamin D 2 ). Ergosterol is an important component of mushrooms. Through ultraviolet b (UVB) irradiation, which can occur within mushroom or artificially, it becomes ergocalciferol [81] . Cholecalciferol comes from animals and people through the biosynthesis of cholesterol to 7-dehydrocholesterol (Provitamin D 3 ). Again, through UVB irradiation, this intermediate becomes cholecalciferol. Thus, dietary intake and sun exposure are the major determinants of serum 25-hydroxyvitamin D levels.

Sun, mainly UVB irradiation, plays an important role in biosynthesis of vitamin D. Since 7-dehydrocholesterol can be synthesized from cholesterol, theoretically vitamin D supplementation is not required once sun exposure is adequate. Skin color is a key determinant of vitamin D synthesis [82] . Vitamin D has been proposed to play a role in human evolution and migration away from equator by affecting skin color through the development of depigmented and tannable skin via genetic pathways under positive selection[1,83]. Sun exposure is highly effective in raising serum 25-hydroxyvitamin D concentration, while its effects diminish significantly on donning clothing and using sun screen [84] . In this regard, more body surface area exposure is more effective than longer exposure time [85] . However, the efficacy of sun exposure to increase serum 25hydroxyvotamin D concentrations diminishes with the degree of skin tanning [86] . Thus, minimized sun exposure time for 5 min to 30 min (depending on time of day, season, latitude, and skin pigmentation) with maximize body surface exposure is recommended[9]. However, increased risk of sun-mediated skin cancer makes this approach to prevent vitamin D deficiency less optimum [87] .

Vitamin D can be obtained through dietary intake. However, except for cod liver oil, vitamin D content in naturally occurring food is relatively low, even in mushrooms (Table 2) . Although ergosterol is highly abundant in the membrane of mushrooms, mushroom are cultivated under shadow without UVB irradiation[81]. Thus, dietary intake of vitamin D is inadequate and vitamin D supplement is often needed to avoid deficiency.

It is estimated that 65% of vitamin D is present as vitamin D while 35% is in the form of 25-hydroxyvitaomn D. As well, almost 75% of vitamin D is in adipose tissue, while 25-hydroxyvitamin D is distributed 20% in muscle, 30% in serum, 35% in fat, and 15% in other tissues [88] . The metabolism of vitamin D 3 and vitamin D 2 is summarized in Table 3 . Vitamin D binding protein transports the various forms of vitamin D in circulation, including vitamin D, 25-hydroxyvtamin D, and 1,25-dihydroxyvitamin D [89] . Each vitamin D binding protein molecule has one binding site for vitamin D and/or its metabolites. The relative affinity of vitamin D binding protein to vitamin D 3 Table 2 is 20 μg (800 IU) for adults and children aged 4 years and older. Foods providing 20% or more of the DV are considered to be high sources of a nutrient, but foods providing lower percentages of the DV also contribute to a healthful diet. DV: Daily value. . These data indicate that vitamin D 3 is more biologically potent than vitamin D 2 .

Vitamin D 2 and vitamin D 3 were reported to have similar efficacy in raising serum 25hydroxyviramin D concentration [ 

The primary function of vitamin D is to maintain calcium homeostasis. 

The maximal allowed serum 25-hydroxyvitamin D concentration is defined by the appearance of adverse effects. Although the Institute of Medicine dose not define maximal serum 25-hydroxyvitamin D concentration[104], a warning against elevated serum 25-hydroxyvitamin D concentrations is stated. This warning is based upon the observed association of increasing mortality with serum 25-hydroxyvitamin D concentration > 125 nmol/L (50 ng/mL)[107] by limiting the maximal daily vitamin D allowance (Table 4 ). This notion was further supported by the finding of increased cardiovascular mortality with serum 25-hydroxyvitaminD > 125 nmol/L (50 ng/mL) [108] . In addition, a progressive decline in bone mineral density with serum 25hydroxyvitamin D greater than 125 nmol/L (50 ng/mL) was observed in a United A Lysine (K) amino acid polymorphism, in replacement of Threonine (T), at position 436 of vitamin D binding protein is associated with increased affinity of vitamin D and is associated a 416% elevation in serum 25-hydroxyvitamin D concentration if highdose (4000 IU) vitamin D 3 replacement therapy if given as opposed to low-dose (600 IU) vitamin D 3 replacement therapy. Individuals carrying the TT SNP showed only a 136% increase in circulating vitamin [125] . Since the K allele is a minor allele and KK genotype accounts for less than few percent of population, the KK subjects may account for the excessive serum 25-hydroxyvitamin D-associated complications noted in certain studies. Given the above, daily vitamin D supplementation would seem to be most physiological and safest way to correct vitamin D deficiency and avoid the possible adverse effects associated with the excessive serum 25-hydroxyvitamin D concentration.

Various genetic loci are associated with serum 25-hydroxyvitamin D concentration [126] with 4 major loci identified (Table 6 ). These are all key proteins involved in the transportation and metabolism of vitamin D. Race and ethnicity were noted to have significant impact on serum 25-dihyrdroxyvitamin D concentration[127], again implicating a genetic influence[126] including skin color [128] .

Seasonable variations in serum 25-hydroxyvitanim D concentrations related to sun exposure are well described [126] . Consistent with this, latitude has a significant impact on serum 25-dihydrocyvitamin D concentration [129] . Living closer to the equator and increasing sun exposure can improve vitamin D levels. However, the increased risk of skin cancer from sun exposure should be balanced employing maximum skin 

As showed in Table 4 , the recommended vitamin D supplement varies between organizations and agencies. The reasons for this relate to the purpose of vitamin D supplementation, visive calcemic vs non-calcemic effects. For calcemic effects, bone health is the goal of supplementation and is maximized through using a conservative daily vitamin D to achieve the minimal serum 25-hydroxyvitamin D concentration while avoiding possible adverse effects associated with overreplacement. A public health approach to this is displayed in Table 7 . In contrast, a more personized approach is rationale when the target is to promote the non-calcemic effects of vitamin D.

We recommend using vitamin D 3 , instead of vitamin D 2 , for the rationale as discussed in the sections 3.2 and 3.3. We are in favor of daily replacement therapy and against intermittent mega dose replacement. This is supported by the recommendations of the Endocrine Society for indefinitely intermittent mega dose replacement [131] . It has been estimated that supplement with cholecalciferol 1000 IU (50 μg) daily will increase serum 25-hydroxyvitamin D concentration by 10 ng/mL [132] . Since vitamin D is a fat soluble, replacement therapy can be further enhanced by taking it with the largest meal of day [133] . We recommend vitamin D 3 1000 IU daily for achievement of an initial serum 25-hydroxyvitamin D concentration between 51 nmol/L (21) ng/mL and 75 nmol/L (30 ng/mL); 2000 IU daily for between 26 nmol/L (11 ng/mL) and 50 nmol/L (20 ng/mL); and 5000 IU for equal or less than 25 nmol/L (10 ng/mL). Serum 25-hydroxyvitamin concentration should be measured within 3 mo for assessment and, if indicated, dose adjustment. We are targeting serum 25hydroxyvitamin D concentration between 75 nmol/L (30 ng/mL) and 125 nmol/L (50 ng/mL).

To date, eight clinical trials employed vitamin D to reduce prediabetes progression to overt diabetes (Table 8) . Only two studies[134,135] demonstrated positive results. Although these two studies had small sample size, they recruited true vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L or 20 ng/mL) subjects and achieved final 25-hydroxyvitamin D concentration at 89-90 nmol/L, after intervention for 1 year and 6 mo, respectively. Of note, the study in India [134] was a randomized open label study demonstrating an odds ratio of 0.31 [95% confidence intervals (CI): 0.11-0.90]. The study in Iran was a randomized placebo control study [135] revealing an odds ratio of 0.06 (95%CI: 0.01-0.51). Because of relatively small sample sizes of both studies, the CI were very wide. Additional studies with similar initial and final 25-hydroxyvitamin D concentration (< 50 nmol/L and 90-100 nmol/L, respectively) and much larger sample sizes are required to confirm these data.

Two negative studies [136, 137] were noted to have similar initial 25-hydroxyvitamin D concentrations (25-42 nmol/L). The negative results could be due to the relatively short interventions (8-16 wk) and small sample sizes. The study in Holland only [138] [139] [140] [141] had a final 25-hydroxyvitamin D concentration > 100 nmol/L which might not be optimal for glucose metabolism. Among them, the study in African American [141] was the only study that recruited true vitamin D deficient subjects (initial 25-hydroxyvitamin D 37 nmol/L). Of note, ergocalciferol was used which could be less effective biologically as discussed above in 3.2 and 3.3. Enrollment of non-vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L) subjects [138] [139] [140] could further reduce the chance of finding any effect. Furthermore, the study in Norway had a significant dropout rate in the interventional group with only 45% of participants completing the planned 5-year visit. The largest intervention trial [138] included more than 1000 subjects in each group. To be able to apply to the general population in the United States, this study did not target vitamin D deficient subjects and allowed the participants to take additional vitamin D up to 25 μg daily. Therefore, it had the highest initial 25-hydroxyvitamin D among these studies, 70 nmol/L in the control group and 69 nmol/L in the interventional group, which might diminish the power of this study to detect the beneficial effect of vitamin D. Regardless of the negative results in most studies, the beneficial effect of vitamin D supplementation cannot be completely excluded, especially in subjects with vitamin D deficiency (25hydroxyvitamin D < 50 nmol/L).

Various parameters of glucose metabolism were reported in most of above-mentioned studies, except one [138] . After vitamin D intervention for 1 year, the study from India [134] observed improvement in fasting and 2-hr post-challenge glucose concentrations, insulin sensitivity by Homeostasis Model (HOMA) insulin resistance index, QUICKI, and 1/fasting insulin concentration while no impact on HbA1c and beta cell function by HOMA. Following vitamin D supplement for 6 mo, the study from Iran [135] reported the improvement in the HOMA insulin resistance index and marginal improvement in fasting insulin concentration (P = 0.05) and 2-hour post-challenge blood glucose concentration (P = 0.07) with no impact on fasting blood glucose concentration.

After an 8-wk intervention, the study from Sweden [136] assessed insulin sensitivity and beta cell function using the hyperglycemic clamp. They observed a significant improvement in deposition index based on the first phase insulin response (P = 0.005) and marginal improvement in first phase insulin response (P = 0.06), insulin sensitive index (P = 0.09), deposition index based on the second phase insulin response (P = 0.06), and A1c (P = 0.06) but no impact on the second phase insulin response and fasting and 2-hr post-challenge blood glucose concentration.

In contrast, the study from Holland[137] evaluated glucose metabolism parameters based on the 75-g glucose tolerance test following intervention for 16 wk. They reported negative results, finding no effects upon insulin area under curve, glucose area under curve, insulin sensitivity by composite insulin sensitivity index, Stumvoll index, insulin resistance index by HOMA, and beta cell function by insulinogenic index. Of note, the final 25-hydroxyvitamin D concentration was only 60 nmol/L which could be suboptimal for glucose metabolism. Similarly, after the vitamin D supplementation for 5 years, the study from Norway [140] observed no impact on fasting and 2-hr post-challenge serum glucose concentration, fasting and post challenge serum insulin concentration, fasting serum C-peptide concentration, HbA1c, and insulin sensitivity by HOMA insulin resistance index and QUICKI.

Following a 12-mo intervention, the study involving Latino and African Americans [139] observed a significant improvement in HbA1c but no effects on fasting and 2-hr post-challenge blood glucose concentration, beta cell function by the ratio of insulin and glucose area under curve, Stumvoll first and second insulin response, insulinogenic index, insulin sensitivity index by HOMA insulin resistance index and composite insulin sensitivity index, and oral disposition index. However, a significant improvement in composite insulin sensitivity index but not Matsuda index, insulinogenic index, C-peptidogenic index, and HbA1c was noted.

Excepting two studies[137,140] with negative results, favorable outcomes on parameters of glucose metabolism were reported in five studies [134] [135] [136] 139, 141] suggesting some benefits to supplementation under these conditions.

In vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L) prediabetic subjects, vitamin D supplement appears to be effective in reduction of the development of overt diabetes. However, there appears to be no benefit in vitamin D sufficient subjects, which was noted in a study from Norway [142] . Based on pooled data from four intervention trials, in subjects without vitamin D deficiency there is no improvement in glucose metabolism with high dose vitamin D supplementation and if anything, the effect is negative [143] . This notion is consistent with the observed threshold effect of vitamin D on bone health and lack of benefit in subjects with baseline 25hydroxyvitamin D level ≥ 75 nmol/L (30 ng/mL)[14,15].

Functional beta cell studies: The important role of vitamin D on insulin secretion has been noted in laboratory animals since 1980. Insulin secretion was reduced by about 50% in isolated perfused islets from vitamin D-deficient rats compared to controls [144] . Interestingly, 1,25-dihydroxyvitamin D 3 was noted in cell nuclei in the islets of langerhans [145] . Furthermore, administration of 1,25-dihydroxyvitamin D3 to vitamin D-deficient rats improved insulin secretion significantly when compared to controls [146] . Vitamin D deficiency impaired both phases of insulin release in rats while correction of hypocalcemia failed to reverse the defect in insulin release [147] . Vitamin D, but not calcium, was essential for normal insulin secretion from the perfused rat pancreas [148] . The positive effect of single dose of 1,25-dihydroxyvitamin D 3 on insulin secretion was apparent at 8 h in perfused rat pancreata, peaked at 14 h, and then decreased to pretreatment baseline values by 36 h [149] . Dietary vitamin D3 supplementation improved impaired glucose tolerance and insulin secretion in the vitamin D-deficient rats [150] . A dose-dependent effect from parenteral 1,25dihydroxyvitamin D on insulin secretion and glucose metabolism was observed within 3 h and remained effective up to 20 h in the vitamin D-deficient rats [151] . The role of vitamin D on insulin synthesis and secretion was supported by studies in vitamin D receptor knockout mice. Insulin secretory capacity was reduced by 60% in vitamin D receptor knockout mice [152] with increased post-challenged blood glucose but normal fasting blood glucose concentration and reduced insulin mRNA levels in pancreatic islets but normal pancreatic beta cell mass, islet architecture, and islet neogenesis when compared to wild type mice. Thus, vitamin D plays an important role in pancreatic insulin synthesis and secretion in vivo.

Mechanistic studies of beta cell function: Although the essential role of vitamin D on insulin secretion has been established in vitamin D depleted laboratory animal, details of the underlying molecular mechanism remain to be defined. Employing a proteomic approach, treatment with 1,25-dihydroxyvitamin D 3 resulted in 31 differentially expressed proteins in INS-1 beta-like cells [153] with 29 upregulated, some of which were implicated in insulin granule motility and insulin exocytosis as well as regulation of ions. Pretreatment of INS1E cells with 1,25-dihydroxyvitamin D or 25hydroxyvitamin D and glucose resulted in 526 and 181 differentially expressed genes, respectively [154] .

Several molecular mechanisms were proposed to account for the effects of vitamin D on beta cells, including changes in the local pancreatic islet renin-angiotensin system [155] , restoration of GLUT2 expression [156] , enhancement of IP3 and AMPA receptor expression [157] , vitamin D-binding protein-induced beta cell dedifferentiation [158] , reduction of oxidative damage [159] , reduced cholinergic pancreatic effects[160], enhanced transcriptional regulation of voltage-gated calcium channels [161] , and elevation of PPAR-γ expression [162] . However, further studies are required to confirm the proposed mechanisms.

Functional studies of insulin sensitivity: In contrast to beta cell function, there are fewer studies of insulin sensitivity. Dietary supplementation of vitamin D improved insulin sensitivity, hepatic steatosis, and myocardial fibrosis in Western diet fed rats [163] . In dietary-induced obese mice, vitamin D receptor activation in liver macrophages improved insulin sensitivity with reduction of hepatic inflammation and steatosis [164] . Vitamin D treatment improved insulin resistance index in a nongenetic model of type 2 diabetes [165] . However, vitamin D status were not reported in these studies.

Mechanistic studies of insulin sensitivity: Chronic central administration of 1,25dihydroxyvitamin D 3 dramatically reduced body weight, putatively by lowering food intake, in obese rodents [166] . Treatment with vitamin D increased mitochondrial function and insulin sensitivity, in part, through upregulation of perilipin 2, a perilipin protein upregulated with 1,25-dihydroxyvitamin D treatment [167] . In skeletal myocytes, vitamin D reduced insulin resistance by altering lipid partitioning and lipid droplet packaging in favor of lipid turnover [168] . FGF-23 knockout mice are hypoglycemic with profoundly increased peripheral insulin sensitivity and improved subcutaneous glucose tolerance. Ablation of vitamin D signaling in these mice normalized subcutaneous glucose tolerance tests and insulin sensitivity [169] . Caveolin-1 protein, which is necessary for vitamin D signaling, could play a role in vitamin D-induced insulin sensitivity in skeletal muscle [170] . In cultured rat osteoblasts, 1,25-dihydroxyvitamin D 3 treatment increased expression of the insulin and vitamin D receptors, and elevated osteocalcin levels under high glucose exposure [171] , which may in turn improve insulin sensitivity.

However, the results of vitamin D receptor knockout mice were less uniform. Skeletal muscle-specific vitamin D receptor knockout mice developed insulin resistance and glucose intolerance accompanied by increased expression and activity of FOXO1 [172] . Deletion of macrophage vitamin D receptor promoted insulin resistance and monocyte cholesterol transport and accelerated atherosclerosis [173] . In contrast, deletion of the vitamin D receptor gene in endothelial cells improved glucose tolerance and insulin sensitivity in skeletal muscle and reduced expression and secretion of insulin in pancreatic islets [174] . Together these data indicate that vitamin D has positive and negative effects on insulin sensitivity that are cell and organ specific.

Due to publicity and potential non-calcemic benefits of vitamin D supplementation, the sale of vitamin D supplements increased significantly and taking vitamin D supplements is common. Thus, there are less true vitamin D deficient subjects available for inclusion in clinical trials. As well, a general lack of funding support for large trials impedes addressing the ability of researchers to address the gaps in knowledge surrounding vitamin D and its beneficial effects.

To obtain the maximal effect of vitamin D, serum 25-hydroxyvitamin D concentration should be maintained in an optimal range, namely between 75 nmol/L (30 ng/mL) and 125 nmol/L (50 ng/mL). Inadequate vitamin D replacement therapy will reduce the chance to observe the expected beneficial effect of vitamin D while adverse effects associated with excessive serum 25-hydroxyvtamin D concentration will also cloud data interpretation. Although mega doses of vitamin D given intermittently could improve compliance in a study protocol, the predicted wide swings in serum 25hydroxyvitamin D concentrations will confound outcomes. It is important in clinical studies to use a proper daily dose to avoid these pitfalls.

The Diabetes Prevention Program demonstrated a 58% (95%CI: 48%-66%) reduction in the incidence of diabetes in the lifestyle intervention group (cumulative incidence of diabetes 14.4% in 1079 participants) and a 31% reduction in diabetes (95%CI: 17%-43%) in the metformin treated group (cumulative incidence of diabetes 21.7% in 1073 participants) when compared to the placebo (cumulative incidence of diabetes 28.9% in 1082 participants) [175] . Insulin sensitivity improved by 61.8% in the lifestyle intervention group and 28.3% in the metformin group [176] . This study can be employed to calculate a sample size sufficient for assessing the effects of vitamin D intervention.

Based on the non-linear relationship of serum 25-hydroxyvotamin D concentration and insulin sensitivity index as we reported[113], we constructed Table 9 . Assuming a linear relationship between improvement in insulin sensitivity and reduction of diabetes from the Diabetes Prevention Program [175, 176] , we calculated the required sample size to detect the reduction of diabetes incidence after vitamin D replacement therapy in a population similar to that of the Diabetes Prevention Program [175] with a power of 0.80 to detect the proposed difference and a type I error rate, alpha, of 0.05 in a clinical trial of 3 years. Starting with a baseline serum 25-hydroxyviyamin D of 25 ng/mL (10 ng/mL), 170 subjects would be needed. Such a study cohort size is not excessive. However, if the baseline serum 25-hydroxyvitamin D is equal or greater than 50 nmol/L (20 ng/mL) the cohort size needed increases markedly. These calculations suggest that all studies to date are flawed secondary to inadequate sample size.

It has been frustrating to confound the published negative reports while ample evidence supports the benefit of vitamin D. Accordingly, we propose these guidelines [177] . Future studies into the effects of vitamin D supplementation need to ensure the proper selection of study subjects, adequate vitamin D replacement to achieve an optimal serum 25-hydroxyvitamin D concentrations, avoidance over-placement to eliminate detrimental effects, and adequate sample size to detect the proposed effects. 

The detrimental effects noted in individuals with serum 25-hydroxyvitamin D concentration above a maximum threshold was observed in a cross-sectional study [109] . Further, improvement in bone density after discontinuation of vitamin D supplementation in osteoporotic patients with elevated serum 25-hydroxyvitamin D concentration was reported [110] . Elevated serum 25-hydroxyvitamin D concentrations were also associated with increased falls and fracture [118] . These reports suggest that assessment of negative effects from elevated serum 25-hydroxyvitamin D concentration may be uncovered with additional study.

Although various evidence suggests the benefit of vitamin D on glucose metabolism, published diabetes prevention trails are not convincing and suffer from improper designed and execution. To address this issue, a well-designed and well-conducted randomized, placebo-control trial to test the effects of vitamin D to limit development of diabetes is warranted, by selecting true vitamin D deficient subjects, achieving optimal but not excessive serum 25-hydroxyvitamin concentration, and enrolling adequate number of subjects. Properly monitoring serum 25-hydroxyvitamin D concentrations is required during the study.

The role of vitamin D in glucose metabolism and fuel homeostasis is supported by a number of observational studies. We reported that serum 25-hydroxyviatmin D concentration accounted for 21.2% of the variation in insulin sensitivity index in univariate analysis and 6.1% by itself among 42% with other covariates in multivariate analysis [178] . We also reported that serum 25-hydroxyviatmin D concentration accounted for 8.2% of the variation in beta cell function in univariate analysis and 4.5% by itself among 25.5% with other covariates in multivariate analysis [179] . Although the intervention studies have failed to provide concordant data for multiple reasons, laboratory studies revealed a number of molecular mechanisms that underlie the effect of vitamin D supporting the important role of the vitamin in glucose metabolism and fuel homeostasis. Since the independent contributions of vitamin D to insulin sensitivity [178] and beta cell function [179] are relatively small, vitamin D deficiency could be the last straw that breaks camel's back in polygenetic and multifactorial diseases, such as diabetes, obesity, and hyperlipidemia.

A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study

Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes

The Multi-Ethnic Study of Atherosclerosis

Increased skin pigment reduces the capacity of skin to synthesise vitamin D3

Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin

Changes in circulating vitamin D levels with loss of adipose tissue

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline

Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety

Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D

Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India

Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with prediabetes?

No Effect of High-Dose Vitamin D Treatment on β-Cell Function, Insulin Sensitivity, or Glucose Homeostasis in Subjects With Abnormal Glucose Tolerance: A Randomized Clinical Trial

Effect of moderate-dose vitamin D supplementation on insulin sensitivity in vitamin D-deficient non-Western immigrants in the Netherlands: a randomized placebo-controlled trial

Vitamin D Supplementation and Prevention of Type 2 Diabetes

High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D

Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes

Effect of high-dose vitamin D repletion on glycemic control in african-american males with prediabetes and hypovitaminosis d

Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels

Supplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Tromsø

Vitamin D deficiency inhibits pancreatic secretion of insulin

Target cells for 1,25 dihydroxyvitamin D3 in the pancreas

Effect of 1,25 dihydroxyvitamin D3 on insulin secretion

Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion

Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas

Time course study of insulin secretion after 1,25-dihydroxyvitamin D3 administration

Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo

Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat

Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor

Discovery of novel vitamin Dregulated proteins in INS-1 cells: a proteomic approach

Vitamin D metabolites influence expression of genes concerning cellular viability and function in insulin producing β-cells (INS1E)

A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets

Effects of vitamin D on insulin secretion and glucose transporter GLUT2 under static magnetic field in rat

Vitamin D3 supplementation increases insulin level by regulating altered IP3 and AMPA receptor expression in the pancreatic islets of streptozotocin-induced diabetic rat

Induction of α cell-restricted Gc in dedifferentiating β cells contributes to stress-induced β-cell dysfunction

25(OH) 2 D 3 Activates Autophagy to Protect against Oxidative Damage of INS-1 Pancreatic Beta Cells

The effect of chronic oral vitamin D supplementation on adiposity and insulin secretion in hypothalamic obese rats

1,25-Dihydroxyvitamin D 3 enhances glucose-stimulated insulin secretion in mouse and human islets: a role for transcriptional regulation of voltage-gated calcium channels by the vitamin D receptor

Vitamin D deficiency impairs glucose-stimulated insulin secretion and increases insulin resistance by reducing PPAR-γ expression in nonobese Type 2 diabetic rats

Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats

Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice

Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats

Hypothalamic Vitamin D Improves Glucose Homeostasis and Reduces Weight

Vitamin D produces a perilipin 2-dependent increase in mitochondrial function in C2C12 myotubes

Calcitriol concomitantly enhances insulin sensitivity and alters myocellular lipid partitioning in high fat-treated skeletal muscle cells

Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice

Does vitamin D status contribute to caveolin-1-mediated insulin sensitivity in skeletal muscle?

Gong P. 1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling

FOXO1 Mediates Vitamin D Deficiency-Induced Insulin Resistance in Skeletal Muscle

Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice

Tie-2Cre mediated deletion of the vitamin D receptor gene leads to improved skeletal muscle insulin sensitivity and glucose tolerance

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

Proposed Guidelines for Future Vitamin D Studies

Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction

Plasma 25-hydroxyvitamin D levels are favorably associated with β-cell function

A special acknowledgement is due to Chiu-Tien Chiu, MD, PhD for his unconditional support to KCC. We are in debt to Jeffrey Isenberg MD, MPH for critical reading and editing of the manuscript.